# AABVX — Abivax ADR · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** AABVX  
**Sources:** 15  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-aabvx-abivax-adr-catalysts-narrative-risks-10539

---

## Important note on asset identity (ticker mismatch)

Before the findings, a critical caveat: your prior knowledge describes the security under ticker **AABVX** as a "fund of funds" that invests in other mutual funds and ETFs advised by American Century — a diversified fund vehicle, not a single equity. However, **every detailed source provided describes Abivax S.A., a clinical-stage biotechnology company that trades under the ticker ABVX** on both Euronext Paris and Nasdaq [[1]](https://markets.businessinsider.com/news/stocks/abivax-to-present-data-on-obefazimod-at-united-european-gastroenterology-ueg-week-2026-1036587331?op=1)[[2]](https://catalystalert.io/company/ABVX)[[5]](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-closing-920-million-public-offering)[[8]](https://www.streetwisereports.com/article/2026/07/06/abivax-sa-abvx-uc-opportunity-oral-therapy-catalyst.html). Abivax's U.S. ADR is reported as **ABVX, not AABVX**.

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-aabvx-abivax-adr-catalysts-narrative-risks-10539 (free to sign up)._